News Release

China Patent and Trade Mark Office Grants Patent for RX50, a Drug Target Implicated in Human Cancers and Neurodegenerative Disorders

• GNI Signs Term Sheet to Acquire Hengshan Pharmaceuticals of Shanghai, China
• Amount and Details of Stock Options as Remuneration for Directors and Corporate Auditors